Study on patient experiences with long-acting injectable HIV prevention
Part of Infections clinical trials.
This study is for people in Louisville who are using or starting long-acting injectable PrEP to prevent HIV. It focuses on understanding your experiences and outcomes with this type of PrEP.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are HIV-negative and have been told by a healthcare provider that you're eligible for PrEP (pre-exposure prophylaxis).
- You are either already on a long-acting injectable PrEP (like cabotegravir or lenacapavir) or will start it within 30 days.
- You receive your PrEP care in Louisville, Kentucky.
- You are not pregnant or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study offers a long-acting injectable form of PrEP (lenacapavir) to prevent HIV in Latine transgender women and gay men in the South. It aims to make HIV prevention easier by providing a shot instead of a daily pill.
This study looks at a long-acting injectable HIV prevention medication (called cabotegravir) to see how well it works in real life. If you are already taking or starting this shot, you may be able to join and help improve HIV prevention care.
This study tests a nurse-led program that offers a long-acting injectable medication (cabotegravir) to prevent HIV. The injection is given every two months, and the program aims to make it easier to access this prevention option at your local health center.
This study follows people who are stopping long-acting injectable PrEP (cabotegravir or lenacapavir). It checks how long the drug stays in your body and helps make sure you stay protected during that time. You'll do monthly video visits, mail in blood samples, and fill out short surveys.
This study looks at how people in the Washington, DC area use HIV prevention services. It focuses on those who are HIV-negative and either new to PrEP, taking daily PrEP pills, or getting long-acting injectable PrEP.
This study tests if giving a long-acting HIV prevention shot (lenacapavir) from a mobile medical van can reach people at risk for HIV in Los Angeles County. You may be able to join if you are HIV negative, at risk for HIV, and are willing to try a shot instead of a daily pill.
Hear when a new HIV Pre-exposure Prophylaxis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.